Keyword: Pfizer

Lilly gets positive abemaciclib phase 3 data, plots 2017 NDA

Eli Lilly was hit earlier this month when rival Novartis became the second, after front-runner Pfizer, to gain FDA approval for its CDK 4/6 inhibitor Kisqali (ribociclib), but a readout from its new phase 3 data has buoyed the Big Pharma nonetheless, as it plots an NDA in Q2.